Facing Ethical Challenges in Rolling Out Antiretroviral Treatment in Resource-Poor Countries: Comment on “They Call It 'Patient Selection' in Khayelitsha”

It is widely acknowledged that the HIV and AIDS pandemic is a global emergency and that cheap, effective treatment should be provided for as many people as possible worldwide. But there are many challenges to rolling out antiretroviral treatment in resource-poor settings. These include the cost of drugs, sustaining their supply and distribution, the complexity of treatment regimens, selection of patients for treatment, shortage of medical and nursing personnel, inadequacy of healthcare facilities, the need for uninterrupted, lifelong treatment, and monitoring for drug resistance. Great efforts, nationally and internationally, are required to meet these challenges
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1017/S0963180106060427
 Save to my reading list
Follow the author(s)
My bibliography
Export citation
Find it on Scholar
Edit this record
Mark as duplicate
Revision history Request removal from index
Download options
PhilPapers Archive

Upload a copy of this paper     Check publisher's policy on self-archival     Papers currently archived: 24,442
External links
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library
References found in this work BETA

No references found.

Add more references

Citations of this work BETA

Add more citations

Similar books and articles
Klaus M. Leisinger (1993). Bioethics Here and in Poor Countries: A Comment. Cambridge Quarterly of Healthcare Ethics 2 (1):5.

Monthly downloads

Added to index


Total downloads

15 ( #296,280 of 1,925,098 )

Recent downloads (6 months)

6 ( #140,829 of 1,925,098 )

How can I increase my downloads?

My notes
Sign in to use this feature

Start a new thread
There  are no threads in this forum
Nothing in this forum yet.